Overview

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Status:
Active, not recruiting
Trial end date:
2022-12-06
Target enrollment:
Participant gender:
Summary
This is a study of oral LY2157299 as monotherapy and in combination with lomustine in participants with recurrent malignant glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Lomustine